Table 2 Summary of reasons for discontinuation of treatment in phase II (6–18 months).
Combination group | SASP alone | MTX alone | |
---|---|---|---|
Intercurrent illness | 1 | — | — |
Side effects | 12 | 10 | 14 |
Lack of effect | 2 | 4 | 2 |
Non‐compliance/lost to follow‐up | 2 | — | — |
Total | 17 | 14 | 16 |
MTX, methotrexate; SASP, sulfasalazine.